Reminder that Merck's Molnupiravir was known to cause cancer, death, birth defects and genetic mutations before the FDA approved it.

In the Viber group where volunteers are studying Ivermectin and Lactoferrin to treat cancer and enlarged prostate, someone in the group asked if it was OK to mix Ivermectin with Molnupiravir. I asked them why they would want to take a poison that causes cancer. They asked me if that was documented. To what extent it's been documented to cause cancer in the public so far, I don't know. Here's what I know:

Molnupiravir was developed in the same program that developed Remdesivir. From Vanderbilt University:

"This (2007) discovery prompted Denison’s lab to look for drugs that could inhibit or bypass the coronavirus’s proofreading ability and slow down its replication. For six years they led the preclinical development of two such drugs, remdesivir and molnupiravir." Mark Denison of Vanderbilt and Ralph Baric of North Carolina collaborated on much of this research. The press doesn't report on Vanderbilt and Mark Denison much for some reason.

The NIH funded Denison's research on Remdesivir and Molnupiravir.

On February 4, 2021, Merck responded to reports that their former product Ivermectin was safe and effective against COVID by saying that Ivermectin had not been proven to be safe and effective in clinical trials. Merck: "It is important to note that, to-date, our analysis has identified:No scientific basis for a potential therapeutic effect against COVID-19 from pre-clinical studies;  No meaningful evidence for clinical activity or clinical efficacy in patients with COVID-19 disease, and;  A concerning lack of safety data in the majority of studies. We do not believe that the data available support the safety and efficacy of ivermectin beyond the doses and populations indicated in the regulatory agency-approved prescribing information."

Merck's statement became the basis that "fact checkers" (professional disinformation employees) used to discredit Ivermectin. Merck was also walking their poisonous cancer-causing, birth defects-causing, genetic mutations-causing Molnupiravir through the clinical trials process at the same time. That should tell you about all you need to know about the clinical trials process right there. Clinical trials are controlled by Pharma. Merck intentionally blocked a safe and effective product (Ivermectin) and received approval for a poison (Molnupiravir) through the clinical trials process, because that's what the clinical trials process was designed to do. (I'll look at the origins of clinical trials in a subsequent article).

Here's a brief timeline:

June 17, 2020. Merck begins recruiting for molnupiravir volunteers.

August 9, 2020. Merck publishes photos of molnupiravir for use in the media.

"These images are downloadable for non-commercial use and for purposes such as news reporting or research. The images may not be modified and must display the following copyright language: Copyright © 2009-2021 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, N.J., U.S.A. All rights reserved."

October 5, 2020. Phase 1 Clinical Trials on Merck's molnupiravir in South Africa show virus mutations.

Clinical Trails.gov, from Merck's molnupiravir study, Phase 1:
"Even under ideal conditions, patients treated with molnupiravir produced viable virus a few days into their course of treatment. The extent of the mutations which appeared due to molnupiravir are significant. In the FDA analysis of Merck’s clinical trial results, the authors note that patients who received molnupiravir showed more viral variation than those who did not, including amino acid substitutions, deletions or insertions in the spike gene, and amino acid changes were scattered throughout the coding sequence. A total of 72 emergent spike substitutions or changes was detected among 38 molnupiravir-treated patients." 

February 4, 2021. Merck discouraged the use of Ivermectin to treat COVID in a press release (as above).

March 6, 2021. Merck announced adverse events of Molnupiravir.

"Of 202 treated participants, no safety signals have been identified and of the 4 serious adverse events reported, none were considered to be study drug related."

June 9, 2021. Merck announced they will receive $1.2 Billion to provide Molnupiravir to the government if Molnupiravir receives an EUA.

October 1, 2021. Merck announced that 7.3% of patients who received Molnupiravir in their trials were hospitalized by day 29, and that 14.1% of their patients had died or been hospitalized by day 29 who received a placebo. (Note that the rate of "COVID" death is at or near zero for doctors using common sense and ivermectin, hydroxychloroquine, etc. Merck found ways to murder more people in Group B than Group A to achieve a deceptive "50 percent reduction.)"

October 11, 2021. Merck Announces Submission of Emergency Use Authorization Application to the U.S. FDA for Molnupiravir.

"Earlier this year, Merck entered into a procurement agreement with the U.S. Government under which the company will supply approximately 1.7 million courses of molnupiravir to the U.S. Government, upon EUA or approval from the U.S. FDA. Additionally, Merck has entered into supply and advance purchase agreements for molnupiravir with other governments worldwide, pending regulatory authorization, and is currently in discussions with additional governments."

November 30, 2021. FDA advisory committee votes 13-10 to give an Emergency Use Authorization to Merck's poison, Molnupiravir. NPR 

"An FDA summary showed that in the second half of the study, patients in the group treated with the drug were more likely to be hospitalized or to die than those who got the placebo. The drug's protection against death seen in the first half of the study didn't hold up in the second half. When asked about this discrepancy by committee chairperson Dr. Lindsey Baden, Dr. Nicholas Kartsonis, a Merck senior vice president, said, "I don't have a satisfying answer to your question."

"I don't think you can ethically say it's OK to give this drug in pregnancy, obviously," said Dr. Janet Cragan of the Centers for Disease Control and Prevention during the deliberations. "But at the same time, I'm not sure you can ethically tell a pregnant woman who has COVID-19 that she can't have the drug if she's decided that's what she needs."

December 13, 2021. The New York Times reports that Merck's COVID treatment molnupiravir causes DNA damage, birth defects, and cancer.

"The problem is that the same compound that interferes in the replication of the virus’s genetic material can also be transformed into one that resembles a building block of DNA. Some scientists are concerned that could cause errors in a patient’s own DNA, or in that of a developing fetus. “If cells are replicating, it means they’re uptaking a version of one of the DNA building blocks derived from molnupiravir and incorporating it,” Dr. Campbell said. How serious a problem is that? A team of researchers at the University of North Carolina studied the use of molnupiravir in isolated hamster cells over 32 days and found that the drug did induce mutations in DNA. Those mutations could “contribute to the development of cancer, or cause birth defects either in a developing fetus or through incorporation into sperm precursor cells,” the authors of that study wrote."

December 23, 2021. The FDA Grants an EUA to Merck for Molnupiravir.

Charles Wright